Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08 2021 - 8:00AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse disease,
today announced that David J. Mazzo, PhD, President and CEO of
Caladrius, will provide a corporate update and participate in
one-on-one investor meetings at the H.C. Wainwright
23rd Annual Global Investment Conference to be held September
13-15, 2021.
The presentation will be available on-demand through the H.C.
Wainwright conference portal, starting at 7:00 a.m. ET on
Monday, September 13, 2021.
If you are an institutional investor and would like to listen to
the Company’s presentation, please click on the following link to
register for the conference:
https://hcwevents.com/annualconference/.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: CLBS16, the
subject of both a recently completed positive Phase 2a study and a
newly initiated Phase 2b study (www.freedom-trial.com) in the U.S.
for the treatment of coronary microvascular dysfunction (“CMD”);
CLBS12 (HONEDRA® in Japan), recipient of orphan designation for
Buerger’s Disease in the U.S. and, in Japan, recipient of a
SAKIGAKE designation and eligible for early conditional approval
for the treatment of critical limb ischemia (“CLI”) and Buerger’s
Disease based on the results of an ongoing clinical trial; and
CLBS201, designed to assess the safety and efficacy of CD34+ cell
therapy as a treatment for diabetic kidney disease (“DKD). For
more information on the Company, please
visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John MendittoVice
President, Investor Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@caladrius.com
Media: Real ChemistryRachel GirardReal ChemistryPhone:
401-477-4030Email: rgirard@realchemistry.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024